Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Incyte Corp (NASDAQ:INCY)

During the Trading Day
103.44 -5.21 / -4.80%
As of 3:59pm ET
Day’s Change
During After-Hours   Switch to standard view »
103.00 -0.44 / -0.43%
Volume: 9.4K
Health Technology

Company Description

Incyte Corp. is a biopharmaceutical company. It focuses on the discovery, development and commercialization of proprietary small molecule drugs to treat serious unmet medical needs. The company's product, Jakafi (ruxolitinib), a JAK1 and JAK2 inhibitor, is currently approved in the U.S. for the treatment of intermediate or high-risk myelofibrosis and is in development as a potential treatment for other cancers. Incyte was founded by Roy A. Whitfield in April 1991 and is headquartered in Wilmington, DE.

Contact Information

Incyte Corp.
1801 Augustine Cut-Off
Wilmington Delaware 19803
P:(302) 498-6700
Investor Relations:
(302) 498-5914



Mutual fund holders62.04%
Other institutional35.49%
Individual stakeholders14.35%

Top Executives

Hervé HoppenotPresident, Chief Executive Officer & Director
David W. GryskaChief Financial Officer & Executive Vice President
Reid M. HuberChief Scientific Officer & Executive VP
Steven H. SteinChief Medical Officer & Senior Vice President
Richard S. LevyChief Drug Development Officer & Executive VP